Functional, biochemical, and pathological effects of repeated oral administration of ochratoxin A to rats.
Ochratoxin A (OTA), a mycotoxin produced by several fungi of Aspergillus and Penicillium species, may contaminate agricultural products, resulting in chronic human exposure. In rats, OTA is a potent nephrotoxin, and repeated administration of OTA for 2 years to rats in doses up to 0.21 mg/kg of body wt resulted in high incidences of renal tumors arising from the proximal tubular epithelial cells. The mechanism of tumor formation by OTA in the kidney is not well-defined, and controversial results regarding mode of action have been published. The aim of this study was to characterize dose-dependent changes induced by OTA by application of clinical chemistry, biochemical markers, and toxicokinetics for a better conclusion on modes of action. Administration of OTA (0, 0.25, 0.5, 1, and 2 mg/kg of body wt) to male F344 rats (n = 3 per group) by oral gavage for 2 weeks resulted in a dose-dependent increase in OTA plasma concentrations and concentrations of OTA in both liver and kidney. Although oxidative stress has been implicated in OTA carcinogenicity, treatment with OTA did not induce overt lipid peroxidation or an increase in 8-oxo-7,8-dihydro-2'deoxyguanosine (8-OH-dG) in kidney. In the kidney, OTA-induced pathology was present at all dose levels administered, with a clear increase in severity related to dose. Pathology was restricted to the outer stripe of the outer medulla and consisted of disorganization of the tubule arrangement, frequent apoptotic cells, and abnormally enlarged nuclei scattered through the S3 tubules. Consistent with the histopathology, a dose-dependent increase in the expression of proliferating cell nuclear antigen (PCNA), indicative of cell proliferation, was observed in kidneys, but not in livers of treated animals. The most prominent change in the composition of urine induced by OTA analyzed by 1H NMR and principal component analysis consisted of a major increase in the excretion of trimethylamine N-oxide. However, typical changes observed with other proximal tubular toxins such as increased excretion of glucose were not observed at any of the doses administered. Similarly, treatment with OTA had no clear effects on clinical chemical parameters indicative of nephrotoxicity, although urinary volume was increased at the higher-dose groups. Taken together, the uncommon changes induced by OTA suggest that a unique mechanism may be involved in OTA nephrotoxicity and carcinogenicity.
Mally
Angela
A
Department of Toxicology, University of Würzburg, Germany.
Völkel
Wolfgang
W
Amberg
Alexander
A
Kurz
Michael
M
Wanek
Paul
P
Eder
Erwin
E
Hard
Gordon
G
Dekant
Wolfgang
W
D000818:Animals; D015415:Biomarkers; D001774:Blood Chemical Analysis; D015153:Blotting, Western; D001835:Body Weight / Q000187:drug effects; D002853:Chromatography, Liquid; D004247:DNA / Q000737:chemistry / Q000187:drug effects / Q000302:isolation & purification; D004305:Dose-Response Relationship, Drug; D007441:Intubation, Gastrointestinal; D007668:Kidney / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008099:Liver / Q000378:metabolism / Q000473:pathology; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D013058:Mass Spectrometry; D009793:Ochratoxins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D010363:Pattern Recognition, Automated; D018809:Proliferating Cell Nuclear Antigen / Q000737:chemistry; D051381:Rats; D011916:Rats, Inbred F344
D015415:Biomarkers; D009793:Ochratoxins; D018809:Proliferating Cell Nuclear Antigen; C025589:ochratoxin A; D004247:DNA